ANA MARLI CHRISTOVAM SARTORI
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Moléstias Infecciosas e Parasitárias, Faculdade de Medicina - Docente
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/48 - Laboratório de Imunologia, Hospital das Clínicas, Faculdade de Medicina
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/48 - Laboratório de Imunologia, Hospital das Clínicas, Faculdade de Medicina
8 resultados
Resultados de Busca
Agora exibindo 1 - 8 de 8
conferenceObject COST-EFFECTIVENESS ANA LYSIS OF INCORPORATION OF THE HPV VACCINE TO THE NATIONAL IMMUNIZATION PROGRAM / NIP OF BRAZIL(2013) NOVAES, H. M. D.; SILVA, G. Azevedo e; AYRES, A.; ITRIA, A.; RAMA, C.; SARTORI, A. M. C.; SOAREZ, P. C. De; CLARK, A.; RESCH, S.- Cost-Effectiveness Analysis of a Universal Infant Immunization Program with Meningococcal C Conjugate Vaccine in Brazil(2011) SOAREZ, Patricia Coelho de; SARTORI, Ana Marli C.; NOBREGA, Laura de Andrade Lagoa; ITRIA, Alexander; NOVAES, Hillegonda Maria DutilhObjective: To analyze the cost-effectiveness of a meningococcal C vaccination program in Brazil. Methods: A hypothetical cohort of 3,194,038 children born in Brazil in 2006 was followed for 10 years. A decision tree model was developed using the TreeAge Pro 2007 software program to compare universal infant vaccination with the current program. Epidemiological and cost estimates were based on data retrieved from National Health Information Systems and the literature. The analysis was conducted from the public health care system and societal perspectives. Costs are expressed in 2006 Brazilian reals (R$). Results: At 94% coverage, the program would avoid 1,218 cases, 210 deaths, and 14,473 life-years lost, a reduction of, respectively, 45%, 44%, and 44%, for the 10-year period. Vaccination costs of R$320.9 million would not be offset by R$ 4 to R$7.9 million decreases in disease treatment costs. A national vaccination program would cost R$ 21,620 per life-year saved from the perspective of the health-care system and R$ 21,896 per life-year saved from society's perspective. Results were most sensitive to case fatality rate, disease incidence, and vaccine cost. Conclusions: A universal childhood vaccination program against meningococcal C proved to be a cost-effective strategy, supporting the recent decision of the Brazilian government. These results could contribute to defining the most favorable price of the vaccine and to monitoring its impact on the population.
conferenceObject NATIONAL SPENDING WITH SCREENING, DIAGNOSIS AND TREATMENT OF CERVICAL CANCER: ESTIMATES BASED ON HEALTH INFORMATION SYSTEMS, BRAZIL, 2006(2013) NOVAES, H. M. D.; SOAREZ, P. C. De; ITRIA, A.; SILVA, G. Azevedo e; SARTORI, A. M. C.; RAMA, C.conferenceObject BUDGET IMPACT ANALYSIS OF VACCINES: WHAT ARE THE METHODOLOGICAL ISSUES?(2017) SOAREZ, P. C. De; SARTORI, A. M.; LEANDRO, R. F.; SILVA, D. R.; SOAREZ, D. S.; CAMPOLINA, A. G.; NOVAES, H. M.conferenceObject A SISTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF VACCINATING ELDERLY WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23)(2017) NISHIKAWA, A. M.; MAINARDI, G. M.; NOVAES, H. M.; SARTORI, A. M.; SOAREZ, P. C. DeconferenceObject SYSTEMATIC REVIEW OF ECONOMIC EVALUATION STUDIES FOR DENGUE VACCINE: HOW VALID ARE THE RESULTS?(2017) SOAREZ, P. C. De; SILVA, A. B.; RANDI, B. A.; NOVAES, H. M.; SARTORI, A. M.conferenceObject REGIONAL COST-EFFECTIVENESS ANALYSIS OF UNIVERSAL CHILDHOOD HEPATITIS A VACCINATION IN BRAZIL(2012) SOAREZ, P. C. De; SARTORI, A. M. C.; NOVAES, H. M. D.; AMAKU, M.; AZEVEDO, R. S.; XIMENES, R. A.; MARTELLI, C. M. T.OBJECTIVES: To conduct a cost-effectiveness analysis of a universal childhood hepatitis A vaccination program in Brazilian regions with different hepatitis A endemicity. METHODS: An age and time-dependent dynamic model was developed to estimate the incidence of hepatitis A for 24 years. The analysis was run separately, according to the pattern of regional endemicity, one for Southern Southeast (low endemicity) and one for the North Northeast Midwest (inter-mediate endemicity). The decision analysis model compared universal childhood vaccination with current program of vaccinating high risk individuals. Epidemiologic and cost estimates were based on data retrieved from a nationwide seroepidemiological survey for viral hepatitis, primary data collection, National Health Information Systems and literature. The analysis was conducted from the healthcare system and societal perspectives. Costs are expressed in 2008 Brazilian reals. RESULTS: In this model a universal national immunization program would have a significant impact on disease epidemiology in all regions, resulting in 64% reduction in the number of cases of icteric hepatitis, 59% reduction in deaths due to disease and a 62 % decrease of life years lost, in a national perspective. With a vaccine price per dose of R$16.89 (US$7.23), vaccination against hepatitis A was a cost-saving strategy in the low and intermediate endemicity regions and in Brazil as a whole from healthcare and society perspective. Results were most sensitive to icteric hepatitis incidence, ambulatory cases and vaccine costs. CONCLUSIONS: Universal childhood vaccination program against hepatitis A could be a cost-saving strategy in all regions of Brazil. These results may be useful for the Brazilian government for vaccine related decisions and for monitoring population impact if the vaccine is included in the National Immunization Program.conferenceObject SYSTEMATIC REVIEW OF BUDGETARY IMPACT ANALYSIS GUIDELINES(2017) RODRIGUES, R. F.; SOAREZ, P. C. De; SILVA, D. R.; CAMPOLINA, A. G.; SARTORI, A. M.; NOVAES, H. M.